ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.49
0.55%
US Tech 100
20,720.80
0.67%
S&P 500
5,956.06
0.01%
US Dollar vs CAD
1.43395
0.01%
Bitcoin
86,395.33
2.76%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Stoke Therapeutics Inc (STOK)

  7. Stoke Therapeutics Inc (STOK) News

STOK

Stoke Therapeutics (STOK)

Stoke Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STOK
DateTimeSourceHeadlineSymbolCompany
02/26/20253:30PMBusiness WireStoke Therapeutics to Present at Upcoming Investor Conferences in MarchNASDAQ:STOKStoke Therapeutics Inc
02/18/20253:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
02/18/20257:00AMBusiness WireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
02/18/20257:00AMGlobeNewswire Inc.Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
01/08/20253:30PMBusiness WireStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
01/07/20256:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
01/07/20256:00AMBusiness WireStoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
01/06/20253:30PMBusiness WireStoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
12/27/20244:23PMEdgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
12/27/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/23/20245:15PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/11/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/11/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/10/20246:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/10/20246:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/09/20243:48PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/06/20244:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
12/06/202411:00AMBusiness WireStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
12/05/20243:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/05/20243:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/04/20246:00AMBusiness WireStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
12/03/20243:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/03/20243:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/02/20247:00AMBusiness WireStoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual MeetingNASDAQ:STOKStoke Therapeutics Inc
11/14/20248:00AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STOKStoke Therapeutics Inc
11/05/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
11/05/20243:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STOKStoke Therapeutics Inc
11/05/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
11/05/20246:00AMBusiness WireStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
11/01/20243:50PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:STOK

Your Recent History

NASDAQ
NVDA
NVIDIA
NASDAQ
RNAZ
TransCode Therapeutics
NYSE
IONQ
IonQ
USOTC
RITE
MineralRite (PK)
USOTC
CBRF
CyberFuels (PK)
USOTC
KRTL
KRTL (PK)
NASDAQ
TSLA
Tesla
USOTC
PSRU
Valiant Eagle (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
CYDY
CytoDyn (QB)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (CE)
NASDAQ
ILLR
Triller
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads